Emgality

Emgality is the brand name for galcanezumab, a human monoclonal antibody that targets calcitonin gene-related peptide (CGRP). It is developed to prevent migraine in adults by interfering with CGRP signaling, which is involved in migraine pathophysiology. By binding CGRP, galcanezumab helps reduce the frequency of migraine attacks.

Administration and dosing guidance: Emgality is given as a subcutaneous injection once monthly. At treatment initiation, a loading approach is commonly used (for example, a loading dose followed by a maintenance monthly dose), with typical monthly maintenance doses around 120 mg after an initial loading dose. Dosing may vary based on regulatory guidance and clinical judgment.

Clinical use and efficacy: In pivotal trials, Emgality reduced the number of monthly migraine days compared with placebo in adults with episodic and, to a degree, chronic migraine. It is used as a preventive therapy rather than for treatment of an acute migraine attack.

Safety and adverse effects: The safety profile is generally favorable but may include injection-site reactions such as pain, redness, or swelling. Other commonly reported effects include constipation and mild upper respiratory tract infections or dizziness. Serious hypersensitivity reactions have been reported, and patients should discontinue use and seek medical care if signs of a severe allergic reaction occur.

Precautions and status: Emgality is indicated for adults and should be used under medical supervision. Contraindications include known hypersensitivity to galcanezumab or any of its components. Pregnancy and breastfeeding considerations should be discussed with a clinician, weighing potential benefits and risks.